InMed Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
INM Nasdaq 2834 https://www.inmedpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for InMed Pharmaceuticals Inc

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board - Apr 18th, 2024 12:00 pm
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration - Apr 16th, 2024 12:00 pm
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies - Apr 4th, 2024 12:00 pm
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance - Mar 20th, 2024 12:30 pm
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update - Feb 13th, 2024 10:41 pm
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer - Feb 9th, 2024 1:00 pm
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET - Jan 18th, 2024 9:41 pm
InMed Pharmaceuticals Provides Business Update and Milestones for 2024 - Jan 16th, 2024 1:00 pm
InMed Announces Results of 2023 Annual General Meeting - Dec 19th, 2023 11:03 pm
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration - Nov 29th, 2023 1:00 pm
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update - Nov 14th, 2023 1:04 pm
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 - Nov 2nd, 2023 12:00 pm
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules - Oct 26th, 2023 11:15 pm
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules - Oct 24th, 2023 8:38 pm
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies - Oct 24th, 2023 11:30 am
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update - Sep 29th, 2023 5:21 pm
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Sep 22nd, 2023 10:15 pm
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference - Sep 7th, 2023 12:30 pm
InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET - Jul 21st, 2023 11:30 am
InMed Provides Update on BayMedica Rare Cannabinoid Business - Jul 20th, 2023 11:30 am